Health economic assessment of Enhertu in breast cancer

13 October 2023 - TLV has produced a health economic assessment of Enhertu (trastuzumab deruxtecan) for the regions.  ...

Read more →

TLV is tasked with carrying out health economic assessments of new drugs against cancer

4 July 2023 - The TLV shall carry out health economic assessments of new drugs to be used in clinics, ...

Read more →

Health economic assessment of Carvykti in the treatment of multiple myeloma

16 June 2023 - TLV has prepared a health economic assessment for the regions for Carvykti (ciltacabtagene autoleucel). ...

Read more →

Health economic assessment of Pluvicto in advanced prostate cancer

12 June 2023 - TLV has produced a health economic assessment for the regions for Pluvicto (Lutetium Lu 177 vipivotide tetraxetan).  ...

Read more →

TLV reconsiders the subsidy of Lumykras (sotorasib)

4 April 2023 - TLV has started a review of Lumykras (sotorasib). Lumykras (sotorasib) has already been included in the high-cost ...

Read more →

TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios

8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...

Read more →

Health economic assessment of Trodelvy in advanced triple negative breast cancer

23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan).  ...

Read more →

Tepmetko is granted a temporary subsidy

16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...

Read more →

Health economic assessment of Abecma in the treatment of multiple myeloma

6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel).  ...

Read more →

Health economic assessment of Blenrep in the treatment of multiple myeloma

6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin).  ...

Read more →

Health economic assessment of Jemperli in endometrial cancer

11 February 2022 - TLV has produced a health economic assessment for the regions for the drug Jemperli (dostarlimab) which is ...

Read more →

Health economic assessment of Opdivo in cancer of the oesophagus or upper gastro-intestinal tract

7 February 2022 - TLV has produced a health economic assessment for the regions for Opdivo (nivolumab).  ...

Read more →

Health economic assessment of Poteligeo in the treatment of mycosis fungoides or Sézary syndrome

11 October 2021 - TLV has produced a health economic assessment for the regions for the drug Poteligeo (mogamulizumab).  ...

Read more →

Health economic assessment of Sarclisa in multiple myeloma

6 September 2021 - TLV has produced a health economic assessment for the regions for the drug Sarclisa (isatuximab) in combination ...

Read more →

EndoPredict for breast cancer - the company chose not to participate with data

19 August 2021 - In November 2020, Myriad Genetics chose to refrain from participating in a health economic assessment of EndoPredict.  ...

Read more →